Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International PRIMACY Bayesian Randomized Controlled Trial.

BACKGROUND Primary percutaneous coronary intervention is used to restore blood flow in the infarct-related coronary artery, followed by immediate stenting to prevent reocclusion. Stents implanted in thrombus-laden arteries cause distal embolization, which paradoxically impairs myocardial reperfusion and ventricular function. Whether a strategy of delayed stenting improves outcomes in patients with acute ST-elevation myocardial infarction (STEMI) is uncertain. METHODS The Primary Reperfusion Secondary Stenting (PRIMACY) is a Bayesian prospective, randomized, open-label, blinded end point trial in which delayed vs immediate stenting in patients with STEMI were compared for prevention of cardiovascular death, nonfatal myocardial infarction, heart failure, or unplanned target vessel revascularization at 9 months. All participants were immediately reperfused, but those assigned to the delayed arm underwent stenting after an interval of 24 to 48 hours. This interval was bridged with antithrombin therapy to reduce thrombus burden. In the principal Bayesian hierarchical random effects analysis, data from exchangeable trials will be combined into a study prior and updated with PRIMACY into a posterior probability of efficacy. RESULTS A total of 305 participants were randomized across 15 centres in France and Canada between April 2014 and September 2017. At baseline, the median age of participants was 59 years, 81% were male, and 3% had a history of percutaneous coronary intervention. Results from PRIMACY will be updated from the patient-level data of 1568 participants enrolled in the Deferred Stent Trial in STEMI (DEFER; United Kingdom), Minimalist Immediate Mechanical Intervention (MIMI; France), Danish Trial in Acute Myocardial Infarction-3 (DANAMI-3; Denmark), and Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST Segment-Elevation Myocardial Infarction (INNOVATION, South Korea) trials. CONCLUSIONS We expect to clarify whether delayed stenting can safely reduce the occurrence of adverse cardiovascular end points compared with immediate stenting in patients with STEMI.

[1]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[2]  Sander Greenland,et al.  Scientists rise up against statistical significance , 2019, Nature.

[3]  V. Torman,et al.  Bayesian models as a unified approach to estimate relative risk (or prevalence ratio) in binary and polytomous outcomes , 2015, Emerging Themes in Epidemiology.

[4]  Akshay S. Desai,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. , 2018, Journal of the American College of Cardiology.

[5]  M. Fusaro,et al.  Deferred vs Immediate Stenting in Primary Percutaneous Coronary Intervention: A Collaborative Meta-analysis of Randomized Trials With Cardiac Magnetic Resonance Imaging Data. , 2018, The Canadian journal of cardiology.

[6]  David J. Spiegelhalter,et al.  Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.

[7]  R. Choi,et al.  INNOVATION Study (Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST-Segment–Elevation Myocardial Infarction) , 2016, Circulation. Cardiovascular interventions.

[8]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[9]  J. Tanguay,et al.  From primary to secondary percutaneous coronary intervention: the emerging concept of early mechanical reperfusion with delayed facilitated stenting-when earlier may not be better. , 2011, The Canadian journal of cardiology.

[10]  P. Croisille,et al.  Comparison of Immediate With Delayed Stenting Using the Minimalist Immediate Mechanical Intervention Approach in Acute ST-Segment–Elevation Myocardial Infarction: The MIMI Study , 2016, Circulation. Cardiovascular interventions.

[11]  C. Terkelsen,et al.  Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial , 2016, The Lancet.

[12]  R. Welsh,et al.  The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada , 2017, PharmacoEconomics - Open.

[13]  K. Isaaz,et al.  A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention , 2006, Coronary artery disease.

[14]  T. Harr,et al.  Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. , 2005, The Cochrane database of systematic reviews.

[15]  P M Fayers,et al.  Tutorial in biostatistics Bayesian data monitoring in clinical trials. , 1997, Statistics in medicine.

[16]  Sunil V. Rao,et al.  Randomized trial of primary PCI with or without routine manual thrombectomy. , 2015, The New England journal of medicine.

[17]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[18]  D. Berry.  Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[19]  James E. Tcheng,et al.  2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials , 2018, Circulation.

[20]  P Bélisle,et al.  Bayesian and mixed Bayesian/likelihood criteria for sample size determination. , 1997, Statistics in medicine.

[21]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[22]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[23]  X. Freixa,et al.  Immediate vs. delayed stenting in acute myocardial infarction: a systematic review and meta-analysis. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[24]  C. Cannon,et al.  Acute myocardial infarction , 2017, The Lancet.

[25]  C. Berry,et al.  A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI) , 2014, Journal of the American College of Cardiology.

[26]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.